RU2686670C2 - Лечение аллергического ринита с использованием комбинации мометазона и олопатадина - Google Patents
Лечение аллергического ринита с использованием комбинации мометазона и олопатадина Download PDFInfo
- Publication number
- RU2686670C2 RU2686670C2 RU2015128496A RU2015128496A RU2686670C2 RU 2686670 C2 RU2686670 C2 RU 2686670C2 RU 2015128496 A RU2015128496 A RU 2015128496A RU 2015128496 A RU2015128496 A RU 2015128496A RU 2686670 C2 RU2686670 C2 RU 2686670C2
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- allergic rhinitis
- specified
- weeks
- person
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 164
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 86
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 62
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 title description 40
- 229960001664 mometasone Drugs 0.000 title description 39
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 title description 24
- 229960004114 olopatadine Drugs 0.000 title description 23
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims abstract description 84
- 229960002744 mometasone furoate Drugs 0.000 claims abstract description 82
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 claims abstract description 78
- 229960003139 olopatadine hydrochloride Drugs 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 230000000694 effects Effects 0.000 claims abstract description 26
- 238000002347 injection Methods 0.000 claims description 73
- 239000007924 injection Substances 0.000 claims description 73
- 208000024891 symptom Diseases 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 24
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 24
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- 230000001186 cumulative effect Effects 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 20
- 239000013566 allergen Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 11
- 208000027993 eye symptom Diseases 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 230000002085 persistent effect Effects 0.000 claims description 6
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 5
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims description 5
- 239000011885 synergistic combination Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 14
- 230000002195 synergetic effect Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 description 63
- 239000007922 nasal spray Substances 0.000 description 47
- 229940097496 nasal spray Drugs 0.000 description 46
- 230000008859 change Effects 0.000 description 33
- 108010058846 Ovalbumin Proteins 0.000 description 24
- 229940092253 ovalbumin Drugs 0.000 description 24
- 206010039083 rhinitis Diseases 0.000 description 20
- 206010041232 sneezing Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 206010028735 Nasal congestion Diseases 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 206010039101 Rhinorrhoea Diseases 0.000 description 11
- 229960004123 mometasone furoate monohydrate Drugs 0.000 description 11
- 241000700198 Cavia Species 0.000 description 10
- 208000036071 Rhinorrhea Diseases 0.000 description 10
- 229940090118 patanase Drugs 0.000 description 10
- 229940075416 dymista Drugs 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- GEVMVZWOOIIINI-KTIJLCEXSA-N 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one;[(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propano Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O GEVMVZWOOIIINI-KTIJLCEXSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003979 eosinophil Anatomy 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 210000001331 nose Anatomy 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 229960004335 azelastine hydrochloride Drugs 0.000 description 5
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229960000289 fluticasone propionate Drugs 0.000 description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 238000011294 monotherapeutic Methods 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- -1 pollen Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 2
- 235000005490 Chenopodium botrys Nutrition 0.000 description 2
- 244000098897 Chenopodium botrys Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000009151 chronic rhinitis Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 201000004356 excessive tearing Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940126602 investigational medicinal product Drugs 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 229940003691 nasonex Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001319 vasomotor rhinitis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000261177 Juniperus flaccida Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3174MU2013 | 2013-10-04 | ||
| IN3174MUM2013 | 2013-10-04 | ||
| PCT/IB2014/065035 WO2015049665A1 (en) | 2013-10-04 | 2014-10-03 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019104453A Division RU2799761C2 (ru) | 2013-10-04 | 2014-10-03 | Лечение аллергического ринита с использованием комбинации мометазона и олопатадина |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2015128496A RU2015128496A (ru) | 2017-11-13 |
| RU2015128496A3 RU2015128496A3 (enExample) | 2018-06-19 |
| RU2686670C2 true RU2686670C2 (ru) | 2019-04-30 |
Family
ID=51982657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015128496A RU2686670C2 (ru) | 2013-10-04 | 2014-10-03 | Лечение аллергического ринита с использованием комбинации мометазона и олопатадина |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10646500B2 (enExample) |
| EP (2) | EP4272839A3 (enExample) |
| JP (3) | JP6419195B2 (enExample) |
| CN (2) | CN105792828A (enExample) |
| HK (1) | HK1215674A1 (enExample) |
| MX (2) | MX2015009429A (enExample) |
| MY (1) | MY176808A (enExample) |
| PH (1) | PH12015502302A1 (enExample) |
| RU (1) | RU2686670C2 (enExample) |
| UA (1) | UA120587C2 (enExample) |
| WO (1) | WO2015049665A1 (enExample) |
| ZA (1) | ZA201504740B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9937189B2 (en) | 2013-09-13 | 2018-04-10 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| US9370483B2 (en) | 2013-09-13 | 2016-06-21 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| US10016443B2 (en) | 2013-10-04 | 2018-07-10 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| HK1215674A1 (zh) * | 2013-10-04 | 2016-09-09 | Glenmark Pharmaceuticals Limited | 结合使用莫米松和奥洛他定治疗过敏性鼻炎 |
| US10653661B2 (en) | 2013-10-04 | 2020-05-19 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10548907B2 (en) | 2013-10-04 | 2020-02-04 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US10758550B2 (en) | 2013-10-04 | 2020-09-01 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| US11679210B2 (en) | 2014-10-03 | 2023-06-20 | Glenmark Specialty S.A. | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
| CN109475495B9 (zh) * | 2017-06-28 | 2023-01-03 | 格兰马克专业公司 | 用于治疗鼻炎的分配装置和药物组合物 |
| HUE071622T2 (hu) * | 2018-02-23 | 2025-09-28 | Glenmark Specialty Sa | Allergiás Rhinitis kezelése gyermekgyógyászati alanyoknál mometazon és olopatadin kombinációjával |
| US12303635B2 (en) | 2018-04-16 | 2025-05-20 | Glenmark Specialty S.A. | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040097474A1 (en) * | 2002-11-12 | 2004-05-20 | Alcon, Inc. | Use of an anti-allergy agent and a steroid to treat nasal conditions |
| WO2009003199A1 (en) * | 2007-06-28 | 2008-12-31 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| RU2444351C2 (ru) * | 2005-09-01 | 2012-03-10 | Биолипокс Аб | Композиция для лечения ринита и родственных заболеваний и способ ее получения |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| PE44995A1 (es) | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| ES2284531T3 (es) | 1999-10-08 | 2007-11-16 | Schering Corporation | Tratamiento nasal topico usando desloratadina y furoato de mometasona. |
| US7977376B2 (en) | 2001-06-27 | 2011-07-12 | Novartis Ag | Olopatadine formulations for topical nasal administration |
| US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| US20060110328A1 (en) | 2004-11-24 | 2006-05-25 | Cagle Gerald D | Method of delivering nasal spray |
| JP2009518300A (ja) | 2005-12-02 | 2009-05-07 | エラン ファーマ インターナショナル リミテッド | モメタゾン組成物ならびにその作製方法および使用方法 |
| BRPI0710654B1 (pt) | 2006-04-21 | 2021-11-03 | Toko Yakuhin Kogyo Kabushiki Kaisha | Preparação de adesivo para pele/mucosa do tipo gel, pulverizável, e sistema de administração usando a preparação |
| KR20110045004A (ko) * | 2008-07-15 | 2011-05-03 | 쉐링 코포레이션 | 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물 |
| WO2010025236A1 (en) | 2008-08-27 | 2010-03-04 | Alexander Goldin | Composition and method for treating colds |
| WO2011008923A2 (en) | 2009-07-17 | 2011-01-20 | Alcon Research, Ltd. | Olopatadine nasal spray regimen for children |
| CN102078285A (zh) * | 2009-11-26 | 2011-06-01 | 天津金耀集团有限公司 | 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶 |
| CN102078326A (zh) * | 2009-11-26 | 2011-06-01 | 天津金耀集团有限公司 | 含有聚维酮碘与糠酸莫米松的局部使用组合物 |
| WO2011141929A2 (en) | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
| PL2736491T3 (pl) | 2011-01-04 | 2017-09-29 | Bausch & Lomb Incorporated | Kompozycje bepotastyny |
| US20150275147A1 (en) | 2012-10-25 | 2015-10-01 | Novozymes A/S | Method for Manual Dish Wash |
| KR20140081925A (ko) | 2012-12-12 | 2014-07-02 | 한미약품 주식회사 | 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제 |
| US9370483B2 (en) | 2013-09-13 | 2016-06-21 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
| MY191380A (en) | 2013-09-13 | 2022-06-21 | Glenmark Specialty Sa | Stabilized fixed dose drug composition having mometasone and olopatadine |
| HK1215674A1 (zh) * | 2013-10-04 | 2016-09-09 | Glenmark Pharmaceuticals Limited | 结合使用莫米松和奥洛他定治疗过敏性鼻炎 |
-
2014
- 2014-10-03 HK HK16103630.2A patent/HK1215674A1/zh unknown
- 2014-10-03 MY MYPI2015702416A patent/MY176808A/en unknown
- 2014-10-03 CN CN201480066538.0A patent/CN105792828A/zh active Pending
- 2014-10-03 JP JP2016546191A patent/JP6419195B2/ja active Active
- 2014-10-03 EP EP23198254.7A patent/EP4272839A3/en active Pending
- 2014-10-03 MX MX2015009429A patent/MX2015009429A/es active IP Right Grant
- 2014-10-03 RU RU2015128496A patent/RU2686670C2/ru active
- 2014-10-03 WO PCT/IB2014/065035 patent/WO2015049665A1/en not_active Ceased
- 2014-10-03 EP EP14802944.0A patent/EP2922553A1/en active Pending
- 2014-10-03 UA UAA201507124A patent/UA120587C2/uk unknown
- 2014-10-03 CN CN202110299649.8A patent/CN112773808A/zh active Pending
- 2014-10-03 US US14/506,122 patent/US10646500B2/en active Active
-
2015
- 2015-07-01 ZA ZA2015/04740A patent/ZA201504740B/en unknown
- 2015-07-22 MX MX2020003035A patent/MX2020003035A/es unknown
- 2015-10-05 PH PH12015502302A patent/PH12015502302A1/en unknown
-
2018
- 2018-04-11 JP JP2018076047A patent/JP6768733B2/ja active Active
-
2020
- 2020-02-21 JP JP2020028523A patent/JP2020097624A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040097474A1 (en) * | 2002-11-12 | 2004-05-20 | Alcon, Inc. | Use of an anti-allergy agent and a steroid to treat nasal conditions |
| RU2444351C2 (ru) * | 2005-09-01 | 2012-03-10 | Биолипокс Аб | Композиция для лечения ринита и родственных заболеваний и способ ее получения |
| WO2009003199A1 (en) * | 2007-06-28 | 2008-12-31 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
Non-Patent Citations (2)
| Title |
|---|
| KAGAWA Y. et al. "Synergetic effects of prednisiline and olo[atadine on atopic dermatitis model of hairless mice". Pharmacology,2010;85(5):286-94, , найдено 08.06.2018 из PubMed PMID:20453552. * |
| KAGAWA Y. et al. "Synergetic effects of prednisiline and olo[atadine on atopic dermatitis model of hairless mice". Pharmacology,2010;85(5):286-94, реферат, найдено 08.06.2018 из PubMed PMID:20453552. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015128496A (ru) | 2017-11-13 |
| US20150099725A1 (en) | 2015-04-09 |
| ZA201504740B (en) | 2016-10-26 |
| JP2016531949A (ja) | 2016-10-13 |
| JP2020097624A (ja) | 2020-06-25 |
| MX2015009429A (es) | 2015-10-09 |
| CN105792828A (zh) | 2016-07-20 |
| JP2018123157A (ja) | 2018-08-09 |
| PH12015502302B1 (en) | 2016-02-15 |
| JP6419195B2 (ja) | 2018-11-07 |
| US10646500B2 (en) | 2020-05-12 |
| CN112773808A (zh) | 2021-05-11 |
| JP6768733B2 (ja) | 2020-10-14 |
| EP4272839A2 (en) | 2023-11-08 |
| PH12015502302A1 (en) | 2016-02-15 |
| EP2922553A1 (en) | 2015-09-30 |
| RU2015128496A3 (enExample) | 2018-06-19 |
| RU2019104453A (ru) | 2019-03-28 |
| UA120587C2 (uk) | 2020-01-10 |
| EP4272839A3 (en) | 2024-01-03 |
| MX2020003035A (es) | 2020-07-22 |
| MY176808A (en) | 2020-08-21 |
| HK1215674A1 (zh) | 2016-09-09 |
| WO2015049665A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2686670C2 (ru) | Лечение аллергического ринита с использованием комбинации мометазона и олопатадина | |
| Baroody et al. | Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis | |
| Bachert et al. | Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis | |
| US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
| NO334441B1 (no) | Preparat for behandling av vanlig forkjølelse. | |
| US9023815B2 (en) | Method for treating rhinitis and sinusitis by rhamnolipids | |
| CN112773765A (zh) | 治疗普拉德-威利综合征的方法 | |
| US10548907B2 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| Okubo et al. | Efficacy and safety of the emedastine patch, a novel transdermal drug delivery system for allergic rhinitis: phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group comparative study in patients with seasonal allergic rhinitis | |
| Abelson et al. | The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model | |
| RU2799761C2 (ru) | Лечение аллергического ринита с использованием комбинации мометазона и олопатадина | |
| HK40095786A (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| Neerati | A textbook of pharmacology-III | |
| Ghimire et al. | Comparative efficacy of steroid nasal spray versus antihistamine nasal spray in allergic rhinitis | |
| CN114007601A (zh) | 用于治疗慢性咳嗽的[((1r,2s,5r)-2-异丙基-5-甲基-环己烷羰基)-氨基]-乙酸异丙酯 | |
| MX2014003546A (es) | Composicion farmaceutica de dosis fija que comprende mometasona y azelastina. | |
| Williams et al. | Abnormal Pharyngeal pH Testing Predicts Response to Proton Pump Inhibitors in Patients with Chronic Cough and Laryngeal Complaints | |
| HK1199815B (en) | Levocetirizine and montelukast for the treatment of influenza and common cold | |
| Werkhäuser et al. | Clinical Study Treatment of Allergic Rhinitis with Ectoine Containing Nasal Spray and Eye Drops in Comparison with Azelastine Containing Nasal Spray and Eye Drops or with Cromoglycic Acid Containing Nasal Spray | |
| Parikh et al. | A Randomized Comparative Study of “New Nasivion Care Drops” in Patients with Nasal Congestion Due to Acute Exacerbation of Allergic Rhinitis | |
| WO2008028324A1 (fr) | Nouvelle préparation de lévamisole pour traiter une rhinite allergique | |
| JP2016535793A (ja) | 口腔アレルギー症候群の予防および治療のための製剤および方法 |